WCLC 2025 - Posters & ePosters-EP.11.19 Efficacy and Safety of Continuing Tislelizumab After Progression of First-Line Tislelizumab in Patients With Advanced NSCLC

EP.11.19 Efficacy and Safety of Continuing Tislelizumab After Progression of First-Line Tislelizumab in Patients With Advanced NSCLC

Back to course

Pdf Summary

This retrospective phase II study evaluated the efficacy and safety of continuing tislelizumab, an anti-PD-1 immunotherapy, in patients with advanced non-small cell lung cancer (NSCLC) who progressed after first-line tislelizumab treatment. Conducted at the Chinese PLA General Hospital from 2020 to 2023, 33 patients with unresectable stage IIIB/IIIC or stage IV NSCLC, lacking EGFR, ALK, or ROS1 mutations, were included. They were divided into two second-line treatment groups: tislelizumab combined with chemotherapy (TisleCT, n=16) and chemotherapy alone (CT, n=17).<br /><br />The primary endpoint was time to treatment failure (TTF) combining first- and second-line therapy. At a median follow-up of approximately 24 months, patients receiving TisleCT showed a longer median TTF in second-line therapy (4.23 vs. 2.76 months; hazard ratio [HR] 0.55) and combined first and second-line therapy (13.57 vs. 9.54 months; HR 0.59) compared to chemotherapy alone.<br /><br />Safety analysis revealed that TisleCT was well tolerated, with most treatment-emergent adverse events (TEAEs) being grade 1-2. No new safety signals emerged from continued tislelizumab use post-progression. Immune-related adverse events occurred in only 12.5% of patients on TisleCT and were mild (grade 1-2).<br /><br />In conclusion, continuing tislelizumab combined with chemotherapy after progression on first-line tislelizumab treatment appears clinically beneficial by prolonging treatment duration and is generally safe for patients with advanced NSCLC. These findings support the potential use of tislelizumab plus chemotherapy as a second-line option post first-line immunotherapy failure in this population.

Asset Subtitle

Boyu Qin

Meta Tag

Speaker Boyu Qin

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

tislelizumab

non-small cell lung cancer

NSCLC

anti-PD-1 immunotherapy

second-line treatment

chemotherapy

time to treatment failure

treatment-emergent adverse events

immune-related adverse events

advanced lung cancer